Advantage Trust Co Has $142,000 Position in Johnson & Johnson (NYSE:JNJ)

Advantage Trust Co increased its holdings in Johnson & Johnson (NYSE:JNJ) by 30.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 981 shares of the company’s stock after buying an additional 230 shares during the period. Advantage Trust Co’s holdings in Johnson & Johnson were worth $142,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of JNJ. Bell Bank grew its position in Johnson & Johnson by 2.7% in the fourth quarter. Bell Bank now owns 4,394 shares of the company’s stock valued at $635,000 after acquiring an additional 115 shares during the last quarter. Indie Asset Partners LLC increased its position in Johnson & Johnson by 3.9% during the 4th quarter. Indie Asset Partners LLC now owns 2,085 shares of the company’s stock worth $302,000 after purchasing an additional 79 shares in the last quarter. Dividend Assets Capital LLC lifted its stake in Johnson & Johnson by 3.4% in the 4th quarter. Dividend Assets Capital LLC now owns 12,321 shares of the company’s stock valued at $1,782,000 after purchasing an additional 403 shares during the last quarter. Eubel Brady & Suttman Asset Management Inc. boosted its position in Johnson & Johnson by 2.1% in the fourth quarter. Eubel Brady & Suttman Asset Management Inc. now owns 138,033 shares of the company’s stock valued at $19,962,000 after buying an additional 2,840 shares in the last quarter. Finally, Hudson Edge Investment Partners Inc. grew its stake in shares of Johnson & Johnson by 0.3% during the fourth quarter. Hudson Edge Investment Partners Inc. now owns 48,987 shares of the company’s stock worth $7,084,000 after buying an additional 154 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on JNJ shares. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Citigroup reduced their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Stifel Nicolaus decreased their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $163.81 on Tuesday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm’s 50-day moving average price is $149.33 and its 200-day moving average price is $155.88. The firm has a market capitalization of $394.38 billion, a P/E ratio of 24.63, a P/E/G ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the firm posted $2.29 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.